Receptor profiling and endocrine interactions of tibolone

Steroids

Volumn 68, Issue 1, 2003, Pages 21-30

  De Gooyer, Marcel E ^a   Deckers, Godefrides H ^a   Schoonen, Willem G E J ^a   Verheul, Herman A M ^a   Kloosterboer, Helenius J ^a  

^a NV ORGANON   (Netherlands)

Author keywords

Androgen receptor; Estrogen receptor; Progesterone receptor; Steroid; Tibolone; Tissue specific effects

Indexed keywords

3ALPHA HYDROXYTIBOLONE; 3BETA HYDROXYTIBOLONE; 4 HYDROXYTAMOXIFEN; ANDROGEN RECEPTOR; ANTIESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ETHINYLESTRADIOL; HORMONE DERIVATIVE; METHYL GROUP; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; NORETHISTERONE; NORETYNODREL; PROGESTERONE RECEPTOR; RALOXIFENE; TAMOXIFEN; TIBOLONE; UNCLASSIFIED DRUG; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; PREGNANE DERIVATIVE; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL STRAIN MCF 7; CHO CELL; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; ENDOMETRIUM; ESTROGEN ACTIVITY; FEMALE; HORMONE ACTION; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOMER; NONHUMAN; OVARIECTOMY; PROTEIN BINDING; PROTEIN STRUCTURE; RABBIT; RAT; TRANSACTIVATION; VAGINA EPITHELIUM; ANIMAL; CELL CULTURE; DOSE RESPONSE; DRUG POTENTIATION; ENDOCRINE SYSTEM; METABOLISM; STRUCTURE ACTIVITY RELATION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCRINE SYSTEM; ENDOMETRIUM; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; HUMANS; NORPREGNENES; PROGESTINS; RABBITS; RATS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, STEROID; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0037211578     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(02)00112-5     Document Type: Article

References (35)

1. Visser de J., Coert A., Feenstra H., Vies van der J. Endocrinological studies with (7α,17α)-17-hydroxy-7-methyl-19-nor-pregn5(10)-en-20-yn-3-one tibolone. Arzneimittelforschung. 34:1984;1010-1017.
2. Markiewicz L., Gurpide E. In vitro evaluation of estrogenic, estrogen antagonistic and progestagenic effects of a steroidal drug (tibolone) and its metabolites on human endometrium. J. Steroid Biochem. 35:1990;535-541.
3. Tax L, Goorissen EM, Kicovic PM. Clinical profile of tibolone. Maturitas 1987;Suppl. 1:3-13.
4. Verhoeven C.H.J., Vos R.M.E., Delbressine L.P.C. The in vivo metabolism of tibolone in animal species. Eur. J. Metab. Pharmacokinet. 27:2002;1-10.
5. Vos R.M.E., Krebbers S.F.M., Verhoeven C.H.J., Delbressine L.P.C. The in vivo human metabolism of tibolone. Drug Metab. Dispos. 30:2002;106-112.
6. Kloosterboer H.J. Tibolone: steroid with a tissue-specific mode of action. J. Steroid. Biochem. Mol. Biol. 76:2001;231-238.
7. Palacios S. Tibolone: what does tissue specific activity mean? Maturitas. 37:2001;159-165.
8. Schoulz von B. The effect of tibolone and conventional HRT on mammographic density. Gynecol. Endocrinol. 14(Suppl.):2000;232.
9. Vies van der J. Pharmacological studies with (7α,17α)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD 14). Maturitas 1987;Suppl. 1:15-24.
10. Zandberg P., Peters J.L.M., Demacker P.N.M., Smit M.J., Reeder de E.G., Meuleman D.G. Tibolone prevents atherosclerotic lesion formation in cholesterol-fed, ovariectomized rabbits. Arterioscler Thromb. Vasc. Biol. 18:1998;1844-1854.
11. Whitehead M.I., Hillard T.C., Crook D. The role and use of progestins. Obstet. Gynecol. 75:1990;59S-76S.
12. Tang B., Markiewicz L., Kloosterboer H.J., Gurpide E. Human endometrial 3-beta-hydroxysteroid dehydrogenase/isomerase can locally reduce estrogenic/progestagenic activity ratios of a steroidal drug (Org OD 14). J. Steroid Biochem. Mol. Biol. 45:1993;345-351.
13. Blom M.J., Groot Wassink M., Wijk van F., Ederveen A.G.H., Kloosterboer H.J., Verhoeven C.H.J.et al. Metabolism of norethisterone and norethisterone derivatives in rat uterus vagina and aorta. Drug Metab. Dispos. 29:2001;976-982.
14. Gooyer de M.E., Overklift Vaupel Kleyn G.T., Smits K.C., Ederveen A.G.H., Verheul H.A.M., Kloosterboer H.J. Tibolone: a compound with tissue specific inhibitory effects on sulfatase. Mol. Cell Endocrinol. 183:2001;55-62.
15. Rubin G.L., Harrold A.J., Mills J.A., Falany C.N., Coughtrie M.W.H. Regulation of sulphotransferase expression in endometrium during the menstrual cycle, by oral contraceptives and during early pregnancy. Mol. Hum. Reprod. 5:1999;995-1002.
16. Horwitz K., Alexander P. In situ photolinked nuclear progesterone receptors of human breast cancer cells. Endocrinology. 113:1983;2195-2201.
17. Vegeto E., Shabnaz M., Wen D., Goldman M.E., O'Malley B., McDonnell D.P. Human progesterone A form is a cell and promoter specific repressor of human progesterone B function. Mol. Endocrinol. 7:1993;1244-1255.
18. Bethea C.L., Widmann A.A. Differential expression of progestin receptor isoforms in the hypothalamus, pituitary, and endometrium of rhesus macaques. Endocrinology. 139:1998;677-687.
19. Wang H., Critchley H.O., Kelly R.W., Shen D., Baird D.T. Progesterone receptor subtype B is differentially regulated in human endometrial stroma. Mol. Hum. Reprod. 4:1998;407-412.
20. Schoonen W.G.E.J., Ries de R.J.H., Joosten J.W.H., Mathijssen-Mommers G.J.W., Kloosterboer H.J. Development of a high-throughput in vitro bioassay to assess potencies of progestagenic compounds using Chinese hamster ovary cells stably transfected with the human progesterone receptor and a luciferase reporter system. Anal. Biochem. 261:1998;222-224.
21. Kuiper G.G.J.M., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J.-Å. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U.S.A. 93:1996;5925-5930.
22. Mosselman S., Polman J., Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 392:1996;49-53.
23. Matsuzaki S., Fukaya T., Suzuki T., Murakami T., Sasano H., Yajima A. Oestrogen receptor α and β mRNA expression in human endometrium throughout the menstrual cycle. Mol. Hum. Reprod. 5:1999;559-564.
24. Petterson K., Delaunay F., Gustafsson J.A. Estrogen receptor beta acts as a dominant regulator of estrogenic signaling. Oncogene. 19:2000;4970-4978.
25. Schoonen W.G.E.J., Joosten J.W.H., Kloosterboer H.J. Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: I. MCF-7 cell lines. J. Steroid Biochem. Mol. Biol. 55:1995;423-437.
26. Bergink E.W., Meel van F., Turpijn E.W., Vies van der J. Binding of progestagens to receptor proteins in MCF-7 cells. J. Steroid Biochem. 19:1983;1563-1570.
27. 50 values of several synthetic (anti)progestagens in vitro in CHO and MCF-7 cells and in vivo in rabbits and rats. J. Steroid Biochem. Mol. Biol. 64:1998;157-170.
28. Finney DJD. Statistical Methods in Biological Assay. 3rd Ed. London: Griffin & Co; 1978.
29. Kicovic P.M., Cortes-Prieto J., Luisi M., Milojevic S., Franchi F. Placebo-controlled cross-over study of effects of tibolone in menopausal women. Reproduction. 6:1982;81-91.
30. Moore R.A. Livial®: a review of clinical studies. Br. J. Obstet. Gynaecol. 106(Suppl. 19):1999;1-21.
31. Loosfelt H., Logeat F., Vu Hai M., Milgrom E. The rabbit progesterone receptor. J. Biol. Chem. 259:1984;14196-14202.
32. Kloosterboer H.J. Tibolone and its metabolites: pharmacology, tissue specificity and effects in animal model tumors. Gynecol. Endocrinol. 11(Suppl. 1):1997;63-68.
33. Critchley H.O.D., Brenner R.M., Henderson T.A., Williams K., Nayak N.R., Slayden O.D.et al. Estrogen receptor β, but not estrogen receptor α, is present in the vascular endothelium of the human and nonhuman primate endometrium. J. Clin. Endocrinol. Metab. 86:2001;1370-1378.
34. Lundström E., Christow A., Svane G., Azavedo E., Söderqvist G., Kersemaekers W.et al. Effects of tibolone and a continuous combined HRT regimen on mammographic breast density. Am. J. Obstet. Gynecol. 186:2002;717-726.
35. Chetrite G., Kloosterboer H.J., Pasqualini J.R. Effect of tibolone (Org OD 14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. Anticancer Res. 17:1997;135-140.